1
|
Orsini Delgado ML, Avril A, Prigent J, Dano J, Rouaix A, Worbs S, Dorner BG, Rougeaux C, Becher F, Fenaille F, Livet S, Volland H, Tournier JN, Simon S. Ricin Antibodies' Neutralizing Capacity against Different Ricin Isoforms and Cultivars. Toxins (Basel) 2021; 13:100. [PMID: 33573016 PMCID: PMC7911099 DOI: 10.3390/toxins13020100] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2020] [Revised: 01/21/2021] [Accepted: 01/25/2021] [Indexed: 12/11/2022] Open
Abstract
Ricin, a highly toxic protein from Ricinus communis, is considered a potential biowarfare agent. Despite the many data available, no specific treatment has yet been approved. Due to their ability to provide immediate protection, antibodies (Abs) are an approach of choice. However, their high specificity might compromise their capacity to protect against the different ricin isoforms (D and E) found in the different cultivars. In previous work, we have shown the neutralizing potential of different Abs (43RCA-G1 (anti ricin A-chain) and RB34 and RB37 (anti ricin B-chain)) against ricin D. In this study, we evaluated their protective capacity against both ricin isoforms. We show that: (i) RB34 and RB37 recognize exclusively ricin D, whereas 43RCA-G1 recognizes both isoforms, (ii) their neutralizing capacity in vitro varies depending on the cultivar, and (iii) there is a synergistic effect when combining RB34 and 43RCA-G1. This effect is also demonstrated in vivo in a mouse model of intranasal intoxication with ricin D/E (1:1), where approximately 60% and 40% of mice treated 0 and 6 h after intoxication, respectively, are protected. Our results highlight the importance of evaluating the effectiveness of the Abs against different ricin isoforms to identify the treatment with the broadest spectrum neutralizing effect.
Collapse
Affiliation(s)
- Maria Lucia Orsini Delgado
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - Arnaud Avril
- Microbiology and Infectious Diseases Department, Anti-Infectious Biotherapies and Immunity Unit, Army Biomedical Research Institute, 91220 Brétigny-sur-Orge, France; (A.A.); (C.R.); (J.-N.T.)
| | - Julie Prigent
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - Julie Dano
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - Audrey Rouaix
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - Sylvia Worbs
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute (RKI), 13353 Berlin, Germany; (S.W.); (B.G.D.)
| | - Brigitte G. Dorner
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute (RKI), 13353 Berlin, Germany; (S.W.); (B.G.D.)
| | - Clémence Rougeaux
- Microbiology and Infectious Diseases Department, Anti-Infectious Biotherapies and Immunity Unit, Army Biomedical Research Institute, 91220 Brétigny-sur-Orge, France; (A.A.); (C.R.); (J.-N.T.)
| | - François Becher
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - François Fenaille
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - Sandrine Livet
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - Hervé Volland
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| | - Jean-Nicolas Tournier
- Microbiology and Infectious Diseases Department, Anti-Infectious Biotherapies and Immunity Unit, Army Biomedical Research Institute, 91220 Brétigny-sur-Orge, France; (A.A.); (C.R.); (J.-N.T.)
| | - Stéphanie Simon
- Paris-Saclay University, CEA, INRAE, Medicines and Healthcare Technologies Department (DMTS), SPI, 91191 Gif-sur-Yvette, France; (J.P.); (J.D.); (A.R.); (F.B.); (F.F.); (S.L.); (H.V.)
| |
Collapse
|